We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Safety/Efficacy Study of Optimizing Ibuprofen Dosing to Achieve Higher PDA Closure Rates (OIDS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00961753
Recruitment Status : Terminated (FDA drug recall on July 30, 2010)
First Posted : August 19, 2009
Last Update Posted : January 28, 2014
Information provided by (Responsible Party):

Study Description
Brief Summary:
The purpose of this study is to determine if increasing the ibuprofen dose will increase the likelihood of closing the patent ductus arteriosus in premature babies.

Condition or disease Intervention/treatment Phase
Patent Ductus Arteriosus Drug: optimized ibuprofen Drug: Standard Ibuprofen Phase 4

Detailed Description:
Failure to close the PDA in premature neonates in a timely fashion can lead to pulmonary over-circulation and systemic under-circulation. The PDA often fails to close using currently approved Ibuprofen dosing regimens, and surgical closure becomes necessary. Ibuprofen clearance in premature neonates is significantly correlated with postnatal age, increasing rapidly over time. Hirt et al. published and optimized dosing scheme for preterm neonates based on pharmacokinetic and pharmacodynamic data. We aim to use this dosing regimen in the clinical setting to determine if increased rates of pharmacologic PDA closure can be achieved.

Study Design

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 10 participants
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Safety and Efficacy of an Optimized Ibuprofen Dosing Regimen Versus Standard Dosing for Pharmacologic Closure of Patent Ductus Arteriosus
Study Start Date : August 2009
Primary Completion Date : October 2010
Study Completion Date : October 2010

Arms and Interventions

Arm Intervention/treatment
Experimental: Optimized Ibuprofen Drug: optimized ibuprofen
day of life 0-3 - 10, 5, 5 mg/kg/dose at 24 hour intervals day of life 4-6 - 14, 7, 7 mg/kg/dose at 24 hour intervals day of life 7-29 - 20, 10, 10 mg/kg/dose at 24 hour intervals
Other Name: neoprofen
Active Comparator: Standard Ibuprofen Drug: Standard Ibuprofen
day of life 0-29 - 10,5, 5 mg/kg/dose at 24 hour intervals
Other Name: neoprofen

Outcome Measures

Primary Outcome Measures :
  1. PDA Closure [ Time Frame: 1-42 days of age ]

Secondary Outcome Measures :
  1. renal function [ Time Frame: 1-30 days of age ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   up to 29 Days   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • All neonates (0-29 days old) less than or equal to 33 post-menstrual age at time of PDA diagnosis requiring nasal CPAP or mechanical ventilation
  • Echo confirmed PDA with a transductal diameter of 1.5 mm or greater and demonstrating a left-to-right shunt
  • Signed informed consent

Exclusion Criteria:

  • Presence of: ductal-dependent congenital heart disease, pulmonary hypertension,
  • Active bleeding (including Grade 3 or 4 IVH)
  • Platelet count < 100,000
  • Coagulopathy
  • Suspected NEC
  • Suspected perforation
  • Creatinine > 1.5
  • Hyperbilirubinemia requiring exchange transfusion
  • Hypotension requiring pressor support
  • Life-threatening congenital malformation
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00961753

United States, Illinois
Children's Hospital of Illinois at OSF Saint Francis Medical Center
Peoria, Illinois, United States, 61637
Sponsors and Collaborators
OSF Healthcare System
Principal Investigator: James R Hocker, MD OSF Healthcare System
More Information

Responsible Party: James Hocker, M.D., OSF Healthcare System
ClinicalTrials.gov Identifier: NCT00961753     History of Changes
Other Study ID Numbers: Ibuprofendosingstudy
First Posted: August 19, 2009    Key Record Dates
Last Update Posted: January 28, 2014
Last Verified: January 2014

Keywords provided by James Hocker, OSF Healthcare System:

Additional relevant MeSH terms:
Ductus Arteriosus, Patent
Heart Defects, Congenital
Cardiovascular Abnormalities
Cardiovascular Diseases
Heart Diseases
Congenital Abnormalities
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action